Acquisition Announced Sponsor buyer
Webster Equity Partners acquisition of Lifecore Biomedical
US$664m equity value
Announced 28 Sep 2026 · NASDAQ: LFCR · US$6.28 cash and scrip per share · 50% premium
Advisers
Lifecore Biomedical
Target
- Financial adviser
- Legal adviser
- Target
- Lifecore Biomedical
- Acquirer
- Webster Equity Partners
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Pharma Services
- Tags
- Pharma Services, Contract Manufacturing, Life Sciences
In the league tables
Similar deals
- Gannet BioChem acquisition of Laysan Bio Feb 2026 · Pharma Services
- Samsung Biologics Co. acquisition of PolyPeptide Group AG Jul 2026 · US$1.5bn · Pharma Services
- Apax Partners acquisition of Gerresheimer global Primary Packaging Plastics business Jul 2026 · US$1.7bn · Packaging
- McKesson acquisition of Precision Medicine Group Aug 2026 · US$2.3bn · Clinical Trial Services
- Veristat acquisition of Certara Regulatory and Medical Writing business Apr 2026 · US$135m · Pharma Services

